Evidence map›Paper›PMID 33558836›Full record

ArticleJournal of virus eradication2021

Commentary title: COVID-19 research, Africa, and global health.

Tinkhani Mbichila, Grace Kumwenda, Ntando Yola, Quarraisha Abdool Karim, Tamar Tchelidze, Joseph Lau, Stephanie Buchholz, Regine Lehnert, Jean-Michel Molina, Kenneth Mayer and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virus eradication, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tinkhani MbichilaForum for Collaborative Research, 1608 Rhode Island Avenue NW, Suite 212, Washington, DC, 20036, USA.
Grace KumwendaPakachere Institute of Health & Development Communication, Delamere House, 4th Floor, South Wing, Victoria Avenue, P.O. Box 30248, Chichiri, Blantyre 3, Malawi.
Ntando YolaDesmond Tutu Health Foundation, Wernher Beit North Bldg. University of, Anzio Rd, Observatory, Cape Town, 7925, South Africa.
Quarraisha Abdool KarimUniversity of Kwa-Zulu Natal, 238 Mazisi Kunene Rd, Glenwood, Durban, 4041, South Africa.
Tamar TchelidzeForum for Collaborative Research, 1608 Rhode Island Avenue NW, Suite 212, Washington, DC, 20036, USA.
Joseph LauForum for Collaborative Research, 1608 Rhode Island Avenue NW, Suite 212, Washington, DC, 20036, USA.
Stephanie BuchholzFederal Institute for Drugs and Medical Devices (BfArM), Germany, Kurt-Gerorg-Kiesinger Allee 3, Bonn, 53175, Germany.
Regine LehnertGHPP-PharmTrain Project, Federal Institute for Drugs and Medical Devices (BfArM), Kurt-Georg-Kiesinger Allee 3, 53175, Bonn, Germany.
Jean-Michel MolinaUniversity of Paris, France and Department of Infectious Diseases, St-Louis and Lariboisière Hospitals, Paris, 1 avenue Claude Vellefaux, 75010, Paris, France.
Kenneth MayerThe Fenway Institute/Harvard Medical School, Ansin Building, 1340 Boylston Street, 8th Floor, Boston, MA, 2215, United States.
Veronica MillerForum for Collaborative Research, 1608 Rhode Island Avenue NW, Suite 212, Washington, DC, 20036, USA.

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
NIAID NIH HHS P30 AI060354
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ANRS, the French National Agency for Research on AIDSART, Antiretroviral TherapyCAPRISA, Centre for the AIDS Programme of Research in South AfricaCRS, Clinical Research SiteEVD, Ebola Virus DiseaseHIV, Human Immunodeficiency SyndromeHPTN, HIV Prevention Trials NetworkIPT, Isoniazid Preventive TherapyLA, long-actingMAb114, single human monoclonal antibody derived from an Ebola survivorPrEP, Pre-Exposure ProphylaxisREGN-EB3, a co-formulated mixture of three human IgG1 monoclonal antibodiesRNA, Ribonucleic AcidrVSV, recombinant vesicular stomatitis virusTasp, Treatment as preventionTB, TuberculosisWHO, World Health OrganizationZMapp, a triple monoclonal antibody agent against Ebola glycoproteins

Identifiers

PMID33558836
PMCPMC7857035

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.